Page last updated: 2024-11-04

vorinostat and Leukopenia

vorinostat has been researched along with Leukopenia in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).

Research Excerpts

ExcerptRelevanceReference
"Vorinostat was administered at the assigned dosage level (100-400 mg, three times weekly) in a standard 3 + 3 dose escalation design."2.90A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. ( Agrawal, A; Baiocchi, R; Blakaj, D; Carrau, R; Diavolitsis, V; Grecula, J; Kang, S; Kumar, B; Kumar, P; Old, MO; Ozer, E; Palettas, M; Pan, Q; Rocco, J; Savvides, P; Teknos, TN; Wei, L, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Teknos, TN1
Grecula, J1
Agrawal, A1
Old, MO1
Ozer, E1
Carrau, R1
Kang, S1
Rocco, J1
Blakaj, D1
Diavolitsis, V1
Kumar, B1
Kumar, P1
Pan, Q1
Palettas, M1
Wei, L1
Baiocchi, R1
Savvides, P1

Trials

1 trial available for vorinostat and Leukopenia

ArticleYear
A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.
    Investigational new drugs, 2019, Volume: 37, Issue:4

    Topics: Anemia; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Drug Eruptions; Female; Head and Neck N

2019